Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kura Oncology (KURA) EBITDA Margin: 2024-2025

Historic EBITDA Margin for Kura Oncology (KURA) over the last 2 years, with Sep 2025 value amounting to -385.53%.

  • Kura Oncology's EBITDA Margin fell 1320713.00% to -385.53% in Q3 2025 from the same period last year, while for Sep 2025 it was -476.31%, marking a year-over-year change of. This contributed to the annual value of -319.11% for FY2024, which is 973616.00% down from last year.
  • Per Kura Oncology's latest filing, its EBITDA Margin stood at -385.53% for Q3 2025, which was up 18.89% from -475.31% recorded in Q2 2025.
  • Kura Oncology's EBITDA Margin's 5-year high stood at 12,821.60% during Q3 2024, with a 5-year trough of -475.31% in Q2 2025.
  • Over the past 2 years, Kura Oncology's median EBITDA Margin value was 4,855.83% (recorded in 2024), while the average stood at 5,874.52%.
  • Data for Kura Oncology's EBITDA Margin shows a maximum YoY slumped of 1,320,713bps (in 2025) over the last 5 years.
  • Kura Oncology's EBITDA Margin (Quarterly) stood at 4,855.83% in 2024, then tumbled by 1,320,713bps to -385.53% in 2025.
  • Its EBITDA Margin stands at -385.53% for Q3 2025, versus -475.31% for Q2 2025 and -458.61% for Q1 2025.